Nextblockbuster

FYI, here is the Zenith footnote on cash needs after the PP

3. Future Operations (continued) As at April 30, 2016, the Company had $0.02 million of cash and is committed to pay $2.5 million of trade and other payables, $0.4 million of promissory notes, $5.7 million due to related parties and $0.8 million for research and development commitments and $0.5 million of lease obligations over the next twelve months as described further in Note 20. In addition, estimated expenditures over the next twelve months under cancellable agreements with contract research organizations conducting the Company’s Phase 1 clinical trial total approximately $3.5 million. As described in Note 23, subsequent to April 30, 2016, the Company closed a private placement of 24,560,500 common shares for gross proceeds of $24.6 million. We believe the Company’s cash as at April 30, 2016, in combination with the cash received subsequent to April 30, 2016 from the private placement, will be sufficient to fund the Company’s contractual commitments for at least the next year, and will be sufficient to fund all of the Company’s liabilities and planned business operations for at least the next year. The Company will require additional capital to fund its planned research, development and corporate activities beyond the next year. The Company will continue to explore alternatives to generate positive cash flow including raising additional equity and/or debt and/or partnering; however, there is no assurance that these initiatives will be successful.

Chicagoest